Developing a robust pipeline of biosimilar products

Phase 1: A global Phase I study in adult male healthy volunteers (CTID: ACTRN12620001341910).

Phase 1: A global Phase I study in adult male healthy volunteers (CTID: CTRI/2023/06/054223).

Phase 1: A global Phase I study in adult male healthy volunteers (CTID: ACTRN12619001287123).

Phase 3: A global Phase III study in male and female patients aged 18 years to 70 years with a newly diagnosed or recurrent Stage IIIB/IV non squamous (ns) non-small cell lung cancer (NSCLC) (CTID: EudraCT2020-005618-16).

Phase 1: A global Phase I study in adult male healthy volunteers (CTID: ACTRN12621000573853).

Phase 3: A global Phase III study in female patients aged 18 to 75 years diagnosed with HER2+ Metastatic Breast Cancer (CTID: CTRI/2020/04/024456).

Phase 1: A global Phase I study in healthy adult male volunteers (CTID: NCT05053334).

Phase 3: A global Phase III study in Patients with Chronic Spontaneous Urticaria Who are Resistant to H1 Antagonist (CTID: EudraCT2022-001745-20).

Phase 1: A global Phase 1 randomized controlled trial in healthy adult volunteers (ACTRN12623000520639).

Phase 3: A global Phase 3 randomized controlled trial in women with post-menopausal osteoporosis. (2023-503790-37-00).

Phase 3: A global Phase III study in adult male and female patients aged 50 years or older with newly diagnosed Wet (Neovascular) Age-Related Macular Degeneration (CTID: EudraCT2021-000590-93).

Product being developed for India and emerging markets.

Phase 3: A Phase III study in Patients with rheumatoid arthritis (CTID: CTRI/2023/01/049000).